Page 319 - 2022_01-Haematologica-web

Letters to the Editor
therapy with novel b-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015;29(6):1267- 1278.
10. Griffiths EA, Golding MC, Srivastava P, et al. Pharmacological target- ing of b-catenin in normal karyotype acute myeloid leukemia blasts. Haematologica. 2015;100(2):e49-e52.
11. Jiang X, Mak PY, Mu H, et al. Disruption of Wnt/b-catenin exerts antileukemia activity and synergizes with FLT3 inhibition in FLT3- mutant acute myeloid leukemia. Clin Cancer Res. 2018;24(10):2417- 2429.
12. Proffitt KD, Madan B, Ke Z, et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mam-
mary cancer. Cancer Res. 2013;73(2):502-507.
13. Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through
the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A.
2013;110(50):20224-20229.
14. Agarwal P, , Zhang B, Ho Y, et al. Enhanced targeting of CML stem
and progenitor cells by inhibition of porcupine acyltransferase in
combination with TKI. Blood. 2017;129(8):1008-1020.
15. Zorko NA, Bernot KM, Whitman SP, et al. Mll partial tandem dupli- cation and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid
leukemias. Blood. 2012; 120(5):1130-1136.
haematologica | 2022; 107(1)
311